Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Regulatory agencies currently recommend itraconazole (ITZ) as a strong cytochrome P450 3A (CYP3A) inhibitor for clinical drug–drug interaction (DDI) studies. This work by an International Consortium for Innovation and Quality in Pharmaceutical Development working group (WG) is to develop and verify...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:CPT Pharmacometrics Syst Pharmacol
Autors principals: Chen, Yuan, Cabalu, Tamara D., Callegari, Ernesto, Einolf, Heidi, Liu, Lichuan, Parrott, Neil, Peters, Sheila Annie, Schuck, Edgar, Sharma, Pradeep, Tracey, Helen, Upreti, Vijay V., Zheng, Ming, Zhu, Andy Z.X., Hall, Stephen D.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6765698/
https://ncbi.nlm.nih.gov/pubmed/31215774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12449
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars